What is Kiromic?
Kiromic BioPharma, Inc. is a clinical-stage biotherapeutics firm focused on immuno-oncology. The company leverages its proprietary DIAMOND AI platform for the discovery and development of cell and gene therapies. Kiromic is advancing ALEXIS, an allogeneic CAR-T cell therapy platform designed to target solid cancers by utilizing gamma delta T-cells. The DIAMOND AI platform aims to significantly reduce the time and cost associated with cellular therapeutic development through advanced data science and target identification.
How much funding has Kiromic raised?
Kiromic has raised a total of $15M across 1 funding round:
Stock Offering
$15M
Stock Issuance/Offering (2020): $15M, investors not publicly disclosed
What's next for Kiromic?
The substantial enterprise-level funding, including the recent strategic investment, positions Kiromic for significant expansion and acceleration of its research and development pipeline. This capital infusion is expected to fuel the advancement of its ALEXIS platform and further validate the capabilities of its DIAMOND AI technology in compressing therapeutic development timelines. The company's focus on immuno-oncology and solid cancer targets suggests a strategic push to address unmet needs in a critical area of oncology.
See full Kiromic company page
